BSA |
Body surface area |
CR |
Complete response |
CTCAE |
Common Terminology Criteria for Adverse Events |
ctDNA |
Circulating tumor DNA |
DLT |
Dose limiting toxicity |
EFS |
Event free survival |
EKG |
Electrocardiogram |
EWS |
Ewing sarcoma |
IV |
Intravascular |
MTD |
Maximum tolerated dose |
mTKI |
multitargeted kinase inhibitors |
PR |
Partial response |
RECIST |
Response Evaluation Criteria in Solid Tumors |
RP2D |
recommended phase 2 dose |
RTK |
Receptor tyrosine kinase |
SD |
Stable disease |
TRAE |
treatment related adverse effect |
VEGFR-2 |
vascular endothelial growth factor receptor 2 |
ULP-WGS |
ultra-low passage whole genome sequencing |
UPC |
urine protein/creatinine |